Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, TG THERAPEUTICS, INC. reported revenue of $616M, up 87.3% year over year. Operating margin was 20.0% and net margin 72.6%, on a free-cash-flow margin of -4.1% with capital expenditure at 0.0% of revenue. Every figure is computed directly from TGTX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $616M | 20.0% | 72.6% |
| FY2024 | $329M | 12.7% | 7.1% |
| FY2023 | $234M | 8.8% | 5.4% |
| FY2022 | $3M | -7839.0% | -8036.3% |
| FY2021 | $7M | -5154.3% | -5204.1% |
How does TGTX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.